Eculizumab in secondary atypical haemolytic uraemic syndrome
Volume: 32, Issue: 3, Pages: 466 - 474
Published: Feb 20, 2017
Abstract
Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 10 9 /L)...
Paper Details
Title
Eculizumab in secondary atypical haemolytic uraemic syndrome
Published Date
Feb 20, 2017
Volume
32
Issue
3
Pages
466 - 474
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History